{"id":"encorafenib-and-binimetinib","safety":{"commonSideEffects":[{"rate":"~50%","effect":"Diarrhea"},{"rate":"~40%","effect":"Fatigue"},{"rate":"~30%","effect":"Nausea"},{"rate":"~20%","effect":"Vomiting"},{"rate":"~25%","effect":"Rash"},{"rate":"~15%","effect":"Elevated liver enzymes"},{"rate":"~1-2%","effect":"Retinal vein occlusion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Encorafenib inhibits BRAF V600E/K mutations, while binimetinib inhibits MEK1/2 downstream in the same pathway. Together, they provide dual inhibition of the MAPK cascade, preventing tumor cell proliferation and survival in BRAF-mutant cancers. This combination approach reduces the emergence of resistance mutations compared to single-agent BRAF inhibition.","oneSentence":"Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:54.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic melanoma with BRAF V600E or V600K mutation"},{"name":"BRAF-mutant colorectal cancer (in combination, pipeline indication)"}]},"trialDetails":[{"nctId":"NCT04074096","phase":"PHASE2","title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2022-09-05","conditions":"Malignant Melanoma, BRAF V600 Mutation, Brain Metastases","enrollment":10},{"nctId":"NCT03915951","phase":"PHASE2","title":"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-04","conditions":"Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT05203172","phase":"PHASE4","title":"The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":46},{"nctId":"NCT04221438","phase":"PHASE2","title":"Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-09-22","conditions":"Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","enrollment":3},{"nctId":"NCT05926960","phase":"PHASE2","title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-06-13","conditions":"Melanoma","enrollment":38},{"nctId":"NCT04657991","phase":"PHASE3","title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Melanoma","enrollment":257},{"nctId":"NCT04741997","phase":"EARLY_PHASE1","title":"Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-05-24","conditions":"Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation","enrollment":50},{"nctId":"NCT01909453","phase":"PHASE3","title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-12","conditions":"Melanoma","enrollment":921},{"nctId":"NCT04903119","phase":"PHASE1","title":"Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma","status":"RECRUITING","sponsor":"Rina Plattner","startDate":"2022-06-01","conditions":"Metastatic Melanoma, BRAF Gene Mutation","enrollment":30},{"nctId":"NCT03543969","phase":"EARLY_PHASE1","title":"Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-14","conditions":"Melanoma (Skin), Skin Cancer, Skin Melanoma","enrollment":14},{"nctId":"NCT05195632","phase":"PHASE2","title":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2022-06-02","conditions":"Non-Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03803553","phase":"PHASE3","title":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-04-16","conditions":"Metastatic Colon Cancer, Stage III Colon Cancer","enrollment":400},{"nctId":"NCT02910700","phase":"PHASE2","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7","enrollment":52},{"nctId":"NCT07256184","phase":"","title":"Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Malignant Melanoma","enrollment":232},{"nctId":"NCT04061980","phase":"PHASE2","title":"Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-10-30","conditions":"BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma","enrollment":24},{"nctId":"NCT04324112","phase":"PHASE2","title":"Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-28","conditions":"Hairy Cell Leukemia","enrollment":45},{"nctId":"NCT05026983","phase":"PHASE2","title":"Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-27","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8","enrollment":35},{"nctId":"NCT05510895","phase":"PHASE2","title":"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2022-09-01","conditions":"Colorectal Cancer, Colon Cancer, BRAF V600E","enrollment":2},{"nctId":"NCT06887088","phase":"PHASE2","title":"Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases","status":"RECRUITING","sponsor":"Grupo Español Multidisciplinar de Melanoma","startDate":"2025-05-29","conditions":"Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases","enrollment":33},{"nctId":"NCT04511013","phase":"PHASE2","title":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2021-01-06","conditions":"Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":112},{"nctId":"NCT07022457","phase":"","title":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","status":"RECRUITING","sponsor":"Pierre Fabre Ltd","startDate":"2025-07-31","conditions":"Metastatic Melanoma, BRAF V600 Mutation Positive","enrollment":50},{"nctId":"NCT03235245","phase":"PHASE2","title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2018-10-30","conditions":"Unresectable Stage III Melanoma, Stage IV Melanoma","enrollment":271},{"nctId":"NCT07092410","phase":"PHASE4","title":"Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib","status":"NOT_YET_RECRUITING","sponsor":"SRH Wald-Klinikum Gera GmbH","startDate":"2025-08","conditions":"Melanoma BRAF V600E/K Mutated","enrollment":101},{"nctId":"NCT05304546","phase":"PHASE2","title":"Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma","status":"COMPLETED","sponsor":"Dr. Ronnie Shapira","startDate":"2023-09-05","conditions":"Malignant Melanoma, Metastatic Melanoma, Immunotherapy","enrollment":1},{"nctId":"NCT03898908","phase":"PHASE2","title":"Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain","status":"COMPLETED","sponsor":"Grupo Español Multidisciplinar de Melanoma","startDate":"2019-07-18","conditions":"Metastatic Melanoma, Brain Metastases","enrollment":48},{"nctId":"NCT05615818","phase":"PHASE3","title":"Personalized Medicine for Advanced Biliary Cancer Patients","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-18","conditions":"Biliary Tract Neoplasms","enrollment":800},{"nctId":"NCT06774989","phase":"","title":"Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-01-02","conditions":"Melanoma (Skin)","enrollment":66},{"nctId":"NCT05954546","phase":"","title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-21","conditions":"Metastatic Melanoma","enrollment":275},{"nctId":"NCT03839342","phase":"PHASE2","title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-06-07","conditions":"Solid Tumor","enrollment":26},{"nctId":"NCT03026517","phase":"PHASE1","title":"Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01","conditions":"Melanoma","enrollment":18},{"nctId":"NCT05097599","phase":"PHASE2","title":"StrataPATH™ (Precision Indications for Approved Therapies)","status":"TERMINATED","sponsor":"Strata Oncology","startDate":"2022-04-29","conditions":"Cancer, Advanced Solid Tumor","enrollment":11},{"nctId":"NCT03973918","phase":"PHASE2","title":"Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-07-29","conditions":"High Grade Glioma, BRAF V600E, BRAF V600K","enrollment":5},{"nctId":"NCT04800822","phase":"PHASE1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-03-17","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT03843775","phase":"PHASE1, PHASE2","title":"A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-02-14","conditions":"Advanced BRAF Mutant Cancers","enrollment":17},{"nctId":"NCT06207656","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2024-04-16","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT03864042","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-02","conditions":"Advanced Solid Tumors, Metastatic Melanoma","enrollment":56},{"nctId":"NCT06470880","phase":"PHASE2","title":"Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2024-06","conditions":"Melanoma","enrollment":40},{"nctId":"NCT02631447","phase":"PHASE2","title":"Sequential Combo Immuno and Target Therapy (SECOMBIT) Study","status":"COMPLETED","sponsor":"Fondazione Melanoma Onlus","startDate":"2016-11-14","conditions":"Metastatic Melanoma","enrollment":251},{"nctId":"NCT04655157","phase":"PHASE1, PHASE2","title":"Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma","status":"TERMINATED","sponsor":"Jason J. Luke, MD","startDate":"2021-05-28","conditions":"Melanoma","enrollment":2},{"nctId":"NCT04390243","phase":"PHASE2","title":"Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation","status":"TERMINATED","sponsor":"Academic and Community Cancer Research United","startDate":"2020-11-16","conditions":"Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma","enrollment":6},{"nctId":"NCT01543698","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05-28","conditions":"Solid Tumors Harboring a BRAF V600 Mutation","enrollment":189},{"nctId":"NCT02159066","phase":"PHASE2","title":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07-23","conditions":"Melanoma","enrollment":158},{"nctId":"NCT03693170","phase":"PHASE2","title":"Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2019-01-17","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":95},{"nctId":"NCT04720768","phase":"PHASE1, PHASE2","title":"Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE","status":"UNKNOWN","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-06-04","conditions":"Melanoma, Metastasis","enrollment":78},{"nctId":"NCT02928224","phase":"PHASE3","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-10-13","conditions":"BRAF V600E-mutant Metastatic Colorectal Cancer","enrollment":702},{"nctId":"NCT02382549","phase":"EARLY_PHASE1","title":"A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2016-04","conditions":"Melanoma","enrollment":8},{"nctId":"NCT02834364","phase":"PHASE2","title":"BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)","status":"COMPLETED","sponsor":"University of Heidelberg Medical Center","startDate":"2016-06","conditions":"Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation","enrollment":12},{"nctId":"NCT05270044","phase":"PHASE3","title":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2022-05-02","conditions":"Melanoma","enrollment":815},{"nctId":"NCT03563729","phase":"PHASE2","title":"Melanoma Metastasized to the Brain and Steroids","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2018-06-06","conditions":"Malignant Melanoma","enrollment":80},{"nctId":"NCT03911869","phase":"PHASE2","title":"An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-04-30","conditions":"Brain Metastases","enrollment":13},{"nctId":"NCT04801966","phase":"NA","title":"Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study","status":"TERMINATED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-09-23","conditions":"Cancer","enrollment":3},{"nctId":"NCT05848219","phase":"","title":"Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-16","conditions":"Metastatic Melanoma","enrollment":543},{"nctId":"NCT05611229","phase":"","title":"Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-16","conditions":"Metastatic Melanoma","enrollment":1975},{"nctId":"NCT03878719","phase":"PHASE1","title":"Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-08-03","conditions":"Melanoma","enrollment":1},{"nctId":"NCT05767879","phase":"PHASE2","title":"(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-01","conditions":"Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma","enrollment":28},{"nctId":"NCT04759846","phase":"PHASE1","title":"Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma","status":"WITHDRAWN","sponsor":"Pierre Fabre Medicament","startDate":"2021-01-21","conditions":"BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma","enrollment":""},{"nctId":"NCT04044430","phase":"PHASE1","title":"Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-08-31","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma","enrollment":2},{"nctId":"NCT05097378","phase":"PHASE2","title":"Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2022-01-01","conditions":"Melanoma, Cancer","enrollment":45},{"nctId":"NCT02902042","phase":"PHASE1, PHASE2","title":"Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2018-04-24","conditions":"Malignant Melanoma","enrollment":16},{"nctId":"NCT04045691","phase":"","title":"Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment","status":"RECRUITING","sponsor":"Pierre Fabre Pharma GmbH","startDate":"2019-10-17","conditions":"Melanoma Stage IV, Melanoma Stage III","enrollment":750},{"nctId":"NCT02263898","phase":"PHASE2","title":"Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2015-01","conditions":"Recurrent Melanoma, Stage IV Melanoma","enrollment":""},{"nctId":"NCT01820364","phase":"PHASE2","title":"LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma","status":"TERMINATED","sponsor":"Array BioPharma","startDate":"2013-11","conditions":"Melanoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Encorafenib: Braftovi / Binimetinib: Mektovi"],"phase":"phase_3","status":"active","brandName":"Encorafenib and Binimetinib","genericName":"Encorafenib and Binimetinib","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells. Used for Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, BRAF-mutant colorectal cancer (in combination, pipeline indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}